Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 3.657
Filter
1.
Hepatología ; 5(3): 204-210, sept. 3, 2024. tab
Article in Spanish | LILACS, COLNAL | ID: biblio-1585318

ABSTRACT

Introducción. El trasplante hepático es el tratamiento de elección para pacientes con enfermedades hepáticas en estadio terminal de cualquier etiología. El éxito de la intervención depende de la adecuada selección del donante y del receptor. Los determinantes biopsicosociales influyen en la tasa de complicaciones y mortalidad postrasplante. El objetivo de este artículo es identificar las intervenciones y los desenlaces clínicos en pacientes con indicación de trasplante hepático que fueron excluidos de la evaluación pretrasplante por los departamentos de psicología y trabajo social entre enero de 2019 y diciembre de 2021 en un centro de referencia de trasplante hepático en Bogotá. Metodología. Estudio de corte transversal en pacientes mayores de edad con indicación clínica de trasplante hepático que no fueron aptos para evaluación pretrasplante durante la valoración de trabajo social y psicología entre enero de 2019 y diciembre de 2021. Resultados. Se identificaron inicialmente 565 candidatos para evaluación pretrasplante de hígado. De estos, 122 pacientes evaluados por los departamentos de psicología y trabajo social no fueron considerados aptos para continuar con la evaluación, y se incluyeron en el estudio. De este grupo, el 58,2 % (n=71) eran hombres, el 77 % (n=94) estaban afiliados al régimen contributivo, y el 38,5 % (n=47) tenían educación primaria como nivel máximo alcanzado. Además, el 34,4 % (n=42) se encontraban desempleados, con una mediana de ingresos mensuales de $1.000.000 COP (RIC $800.000-$1.950.000). Un total de 32,5 % (n=37) de estos pacientes lograron ser incluidos en el estudio pretrasplante después de recibir alguna intervención. Se observaron diferencias significativas en la activación de la red familiar extensa entre el grupo de pacientes incluidos y no incluidos en el estudio pretrasplante (48,6 % vs 0,0 %). Conclusión. Las intervenciones realizadas por el grupo de soporte multidisciplinario de trasplante permiten aumentar el acceso a la evaluación pretrasplante, el ingreso a la lista de espera y el trasplante de pacientes inicialmente no aptos por diferentes causales modificables con estas herramientas.


Introduction. Liver transplantation is the treatment of choice for patients with end-stage liver disease of any etiology. The success of the intervention depends on the appropriate selection of both donor and recipient. Biopsychosocial determinants influence the rate of complications and post-transplant mortality. The objective of this article is to identify interventions and clinical outcomes in patients indicated for liver transplantation who were excluded from pre-transplant evaluation by the psychology and social work departments between January 2019 and December 2021 at a liver transplant referral center in Bogotá. Methodology. Cross-sectional study conducted on adult patients clinically indicated for liver transplantation who were deemed ineligible for pre-transplant evaluation during the social work and psychology assessments between January 2019 and December 2021. Results. Initially, 565 candidates for liver pre-transplant evaluation were identified. Among these, 122 patients evaluated by the psychology and social work departments were not deemed suitable to proceed with evaluation and were included in the study. Of this group, 58.2% (n=71) were male, 77% (n=94) were affiliated with the contributory regime, and 38.5% (n=47) had only completed primary education. Additionally, 34.4% (n=42) were unemployed, with a median monthly income of $1,000,000 COP (IQR $800,000-$1,950,000). A total of 32.5% (n=37) of these patients were eventually included in the pre-transplant study after receiving some form of intervention. Significant differences were observed in the activation of extended family networks between the group of patients included and not included in the pre-transplant study (48.6% vs 0.0%). Conclusion. Interventions conducted by the multidisciplinary transplant support team increase access to pre-transplant evaluation, waiting list inclusion, and transplantation for initially ineligible patients due to various modifiable causes addressed by these tools.


Subject(s)
Humans , Liver Transplantation , Postoperative Complications , Liver , Liver Diseases
2.
Neumol. pediátr. (En línea) ; 19(2): 63-66, jun. 2024. tab, ilus
Article in Spanish | LILACS | ID: biblio-1566995

ABSTRACT

La enfermedad hepática relacionada con fibrosis quística se observa en el 10% de las personas portadoras de la enfermedad. La terapia con moduladores ha mejorado la morbimortalidad, pero teniendo en cuenta que presentan efectos secundarios infrecuentes es necesario monitorizar. Se analiza el algoritmo propuesto por Eldredge et al, que sugiere las decisiones a tomar basado en el resultado de perfil hepático y su aplicación en la práctica clínica.


Cystic fibrosis-related liver disease is seen in 10% of people with the disease. Therapy with modulators has improved morbidity and mortality, but taking into account that they present infrequent side effects, monitoring is necessary. The algorithm proposed by Eldredge et al is analyzed, which suggests the decisions to be made based on the liver profile result and its application in clinical practice.


Subject(s)
Humans , Child , Cystic Fibrosis Transmembrane Conductance Regulator/adverse effects , Cystic Fibrosis/complications , Cystic Fibrosis/drug therapy , Liver Diseases/etiology , Liver Diseases/prevention & control
3.
Enferm. foco (Brasília) ; 15: 1-10, maio. 2024. ilus, tab
Article in Portuguese | LILACS, BDENF | ID: biblio-1572940

ABSTRACT

Objetivo: Identificar as estratégias utilizadas para o diagnóstico precoce da cirrose hepática, considerando reflexões sobre a atuação do (a) enfermeiro (a) nesse processo, principalmente, no contexto da Atenção Primária à Saúde. Métodos: Revisão integrativa da literatura. As buscas foram realizadas nas bases de dados indexadas na Biblioteca Virtual de Saúde e no portal PubMed. Incluiu-se artigos originais, textos completos disponíveis gratuitamente, na íntegra, publicados entre janeiro de 2013 e fevereiro de 2024 nos idiomas inglês, português e espanhol. Resultados: Levantou-se 5471, sendo que 1771 foram descartadas por duplicação. Os critérios de elegibilidade resultaram em 65 artigos. Após análise criteriosa, 45 artigos formaram a amostra final. Conclusão: Evidenciou-se que são distintas as estratégias para a detecção da cirrose em sua fase inicial, sendo estas, em sua maioria, aplicáveis ao contexto da Atenção Primária à Saúde e correlacionadas com a atuação de enfermeiros (as). (AU)


Objective: To identify the strategies used for the early diagnosis of liver cirrhosis, considering reflections on the role of nurses in this process, mainly in the context of Primary Health Care. Methods: Integrative literature review. The searches were carried out in databases indexed in the Virtual Health Library and on the PubMed portal. Original articles were included, complete texts available for free, in full, published between January 2013 and February 2024 in English, Portuguese and Spanish. Results: 5471 were collected, 1771 of which were discarded due to duplication. The eligibility criteria resulted in 65 articles. After careful analysis, 45 articles formed the final sample. Conclusion: It was evident that the strategies for detecting cirrhosis in its initial phase are different, most of which are applicable to the context of Primary Health Care and correlated with the work of nurses. (AU)


Objetivo: Objetivo: Identificar las estrategias utilizadas para el diagnóstico precoz de la cirrosis hepática, considerando reflexiones sobre el papel del enfermero en ese proceso, principalmente en el contexto de la Atención Primaria de Salud. Métodos: Revisión integrativa de la literatura. Las búsquedas se realizaron en bases de datos indexadas en la Biblioteca Virtual en Salud y en el portal PubMed. Se incluyeron artículos originales, textos completos disponibles de forma gratuita, íntegros, publicados entre enero de 2013 y febrero de 2024 en inglés, portugués y español. Resultados: Se recolectaron 5471, de los cuales 1771 fueron descartados por duplicación. Los criterios de elegibilidad resultaron en 65 artículos. Después de un análisis cuidadoso, 45 artículos formaron la muestra final. Conclusión: Se evidenció que las estrategias para detectar la cirrosis en su fase inicial son diferentes, la mayoría de las cuales son aplicables al contexto de la Atención Primaria de Salud y correlacionadas con el trabajo del enfermero. (AU)


Subject(s)
Liver Cirrhosis , Patient Care Team , Early Diagnosis , Liver Diseases
4.
Arch. argent. pediatr ; 122(1): e202202934, feb. 2024. tab, ilus
Article in English, Spanish | LILACS, BINACIS | ID: biblio-1525294

ABSTRACT

La pileflebitis es definida como la trombosis supurativa de la vena porta como complicación de infecciones abdominales. En pediatría, la etiología más frecuente es la apendicitis, generalmente de diagnóstico tardío, que se presenta como sepsis, con una elevada mortalidad. Para el diagnóstico son necesarios métodos de diagnóstico por imágenes; los más utilizados son la ecografía Doppler y la angiotomografía. El tratamiento se basa en la intervención quirúrgica, la antibioticoterapia y la anticoagulación. Esta última tiene indicación controvertida, pero podría mejorar el pronóstico y disminuir la morbimortalidad. Se presenta un caso clínico de pileflebitis secundaria a sepsis por Escherichia coli con punto de partida en una apendicitis aguda, en un paciente pediátrico que evoluciona a la transformación cavernomatosa de la vena porta. Es de importancia conocer el manejo de esta entidad, ya que, una vez superado el cuadro inicial, requerirá un minucioso seguimiento por la posibilidad de evolucionar a la insuficiencia hepática.


Pylephlebitis is defined as suppurative thrombosis of the portal vein as a complication of abdominal infections. In pediatrics, the most frequent etiology is appendicitis, generally of late diagnosis, presenting as sepsis, with a high mortality rate. Imaging methods are necessary for diagnosis; the most common are the Doppler ultrasound and computed tomography angiography. Treatment is based on surgery, antibiotic therapy, and anticoagulation. The indication for the latter is controversial, but it may improve prognosis and decrease morbidity and mortality. Here we describe a clinical case of pylephlebitis secondary to Escherichia coli sepsis, which started as acute appendicitis in a pediatric patient who progressed to cavernomatous transformation of the portal vein. It is important to know the management of this disease because, once the initial symptoms are overcome, it will require close follow-up due to a potential progression to liver failure.


Subject(s)
Humans , Child , Appendicitis/diagnosis , Thrombophlebitis/diagnosis , Thrombophlebitis/etiology , Thrombophlebitis/drug therapy , Sepsis/etiology , Liver Diseases , Portal Vein , Anti-Bacterial Agents/therapeutic use
5.
Article in English | WPRIM | ID: wpr-1010119

ABSTRACT

BACKGROUND@#Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) has become a global epidemic, and air pollution has been identified as a potential risk factor. This study aims to investigate the non-linear relationship between ambient air pollution and MASLD prevalence.@*METHOD@#In this cross-sectional study, participants undergoing health checkups were assessed for three-year average air pollution exposure. MASLD diagnosis required hepatic steatosis with at least 1 out of 5 cardiometabolic criteria. A stepwise approach combining data visualization and regression modeling was used to determine the most appropriate link function between each of the six air pollutants and MASLD. A covariate-adjusted six-pollutant model was constructed accordingly.@*RESULTS@#A total of 131,592 participants were included, with 40.6% met the criteria of MASLD. "Threshold link function," "interaction link function," and "restricted cubic spline (RCS) link functions" best-fitted associations between MASLD and PM2.5, PM10/CO, and O3 /SO2/NO2, respectively. In the six-pollutant model, significant positive associations were observed when pollutant concentrations were over: 34.64 µg/m3 for PM2.5, 57.93 µg/m3 for PM10, 56 µg/m3 for O3, below 643.6 µg/m3 for CO, and within 33 and 48 µg/m3 for NO2. The six-pollutant model using these best-fitted link functions demonstrated superior model fitting compared to exposure-categorized model or linear link function model assuming proportionality of odds.@*CONCLUSION@#Non-linear associations were found between air pollutants and MASLD prevalence. PM2.5, PM10, O3, CO, and NO2 exhibited positive associations with MASLD in specific concentration ranges, highlighting the need to consider non-linear relationships in assessing the impact of air pollution on MASLD.


Subject(s)
Humans , Nitrogen Dioxide , Cross-Sectional Studies , Air Pollution/analysis , Air Pollutants/analysis , Particulate Matter/analysis , Liver Diseases , Environmental Exposure/analysis
6.
Article in English | WPRIM | ID: wpr-1011010

ABSTRACT

Polysaccharides, predominantly extracted from traditional Chinese medicinal herbs such as Lycium barbarum, Angelica sinensis, Astragalus membranaceus, Dendrobium officinale, Ganoderma lucidum, and Poria cocos, represent principal bioactive constituents extensively utilized in Chinese medicine. These compounds have demonstrated significant anti-inflammatory capabilities, especially anti-liver injury activities, while exhibiting minimal adverse effects. This review summarized recent studies to elucidate the hepatoprotective efficacy and underlying molecular mechanisms of these herbal polysaccharides. It underscored the role of these polysaccharides in regulating hepatic function, enhancing immunological responses, and improving antioxidant capacities, thus contributing to the attenuation of hepatocyte apoptosis and liver protection. Analyses of molecular pathways in these studies revealed the intricate and indispensable functions of traditional Chinese herbal polysaccharides in liver injury management. Therefore, this review provides a thorough examination of the hepatoprotective attributes and molecular mechanisms of these medicinal polysaccharides, thereby offering valuable insights for the advancement of polysaccharide-based therapeutic research and their potential clinical applications in liver disease treatment.


Subject(s)
Humans , Drugs, Chinese Herbal/pharmacology , Liver Diseases/drug therapy , Antioxidants , Polysaccharides/therapeutic use , Medicine, Chinese Traditional
7.
Acta Medica Philippina ; : 54-72, 2024.
Article in English | WPRIM | ID: wpr-1016812

ABSTRACT

Background@#Children with COVID-19 may present with gastrointestinal (GI) symptoms and liver dysfunction.@*Objective@#To determine the type and prevalence of gastrointestinal (GI) and hepatic manifestations of COVID-19 in children and its association with severity of illness.@*Methods@#A systematic literature search was done from inception until January 4, 2021 using PubMed, Cochrane Library, Google Scholar and prepublication repositories with no language restrictions. Studies that reported the demographic and clinical features of children with COVID-19 and provided data on their GI and hepatic signs and symptoms were included. Prevalence of GI and hepatic manifestations were pooled using Stata14.@*Results@#We included 58 studies with total of 4497 participants. Overall, one-third of children with COVID-19 presented with at least one GI symptom (33.8%; 95% confidence interval (CI) 23.0, 45.4; I2 97.5%; 42 studies, 3327 participants) with abdominal pain, nausea or vomiting, and diarrhea each occurring in approximately 20%. Children with severe COVID-19 were more likely to present with GI symptoms (odds ratio 2.59; 95% CI 1.35, 4.99; I2 24%; 4 studies, 773 participants). The pooled prevalence of elevated transaminases was 11% for both AST (11.3%, 95% CI 4.9, 19.3; I2 74.7%; 11 studies, 447 participants) and ALT (11.2%, 95% CI 7.1, 16.0; I2 40.8%; 15 studies, 513 participants). Hepatic findings such as jaundice (2-17%), hepatomegaly (2%) or behavioral changes (2%) from hepatic encephalopathy were variably reported by a few studies. The degree of heterogeneity was not improved on exclusion of studies with poor quality, but markedly improved on subgroup analysis according to geographical region and presence of MIS-C. Studies from China showed that children with COVID-19 had significantly lower pooled prevalence for any of the GI symptoms with low degree of heterogeneity, particularly for diarrhea, nausea/vomiting, and abdominal pain, all of which had I2 of 0%. Those with multisystem inflammatory syndrome in children (MIS-C) had significantly more common GI symptoms and increased transaminases than those without.@*Conclusion@#One-third of children with COVID-19 exhibit at least one GI symptom and more likely present in those with severe disease. Elevated transaminases were present in 10%. Prevalence of GI and hepatic manifestations were higher among children with MIS-C.


Subject(s)
COVID-19 , Liver Diseases
8.
Braz. j. biol ; 84: e253061, 2024. tab, graf, ilus
Article in English | LILACS, VETINDEX | ID: biblio-1364520

ABSTRACT

Liver fibrosis is initial stage of any chronic liver disease and its end stage is develops into cirrhosis. Chronic liver diseases are a crucial global health issue and the cause of approximately 2 million deaths per year worldwide. Cirrhosis is currently the 11th most common cause of death globally. Mesenchymal stem cell (MSCs) treatment is the best way to treat acute and chronic liver disease. The aim of this study is to improve the therapeutic potential of MSCs combined with melatonin (MLT) to overcome CCl4-induced liver fibrosis and also investigate the individual impact of melatonin and MSCs against CCl4-induced liver impairment in animal model. Female BALB/c mice were used as CCL4-induced liver fibrotic animal model. Five groups of animal model were made; negative control, Positive control, CCl4+MSCs treated group, CCl4+MLT treated group and CCl4+MSCs+MLT treated group. Cultured MSCs from mice bone marrow were transplanted to CCl4-induced liver injured mice model, individually as well as together with melatonin. Two weeks after MSCs and MLT administration, all groups of mice were sacrificed for examination. Morphological and Histopathological results showed that combined therapy of MSCs+MLT showed substantial beneficial impact on CCl4-induced liver injured model, compared with MSCs and MLT individually. Biochemically, considerable reduction was observed in serum bilirubin and ALT levels of MLT+MSC treated mice, compared to other groups. PCR results shown down-regulation of Bax and up-regulation of Bcl-xl and Albumin, confirm a significant therapeutic effect of MSCs+MLT on CCI4-induced liver fibrosis. From the results, it is concluded that combined therapy of MSCs and MLT show strong therapeutic effect on CCL4-induced liver fibrosis, compared with MSCs and MLT individually.


A fibrose hepática é a fase inicial de qualquer doença hepática crônica, e em sua fase final desenvolve-se para cirrose. As doenças hepáticas crônicas são uma questão de saúde global crucial e a causa de aproximadamente 2 milhões de mortes por ano em todo o mundo. A cirrose, hoje em dia, é a 11ª causa mais comum de morte globalmente. O tratamento da célula-tronco mesenquimal (MSCs) é uma maneira eletiva de tratar a doença hepática aguda e crônica. O objetivo deste estudo é melhorar o potencial terapêutico dos MSCs combinados com a melatonina (MLT) para superar a fibrose hepática induzida por CCl4 e também investigar o impacto individual da melatonina e MSCs contra o comprometimento do fígado induzido por CCl4 no modelo animal. Os ratos BALB / C fêmeas foram usados ​​como modelo de animal fibrótico de fígado induzido por CCl4. Cinco grupos de modelo animal foram feitos: Controle Negativo, Controle Positivo, CCl4 + MSCs Tratados Grupo, Grupo Tratado CCl4 + MLT e Grupo Tratado CCl4 + MSCs + MLT. MSCs cultivados da medula óssea dos ratos foram transplantados para o modelo de camundongos de fígado induzido por CCl4, individualmente, bem como em conjunto com a melatonina. Duas semanas após a administração MSCs e MLT, todos os grupos de camundongos foram sacrificados para o exame. Os resultados morfológicos e histopatológicos mostraram que a terapia combinada do MSCs + MLT mostrou impacto benéfico substancial no modelo ferido no fígado induzido pelo CCl4, em comparação com o MSCs e o MLT individualmente. A redução bioquimicamente considerável foi observada em bilirrubina sérica e níveis ALT de ratinhos tratados com MLT + MSCs, em comparação com outros grupos. Os resultados de PCR mostraram regulação negativa do BAX e regulação positiva do BCL-XL e da albumina, confirmando um efeito terapêutico significativo do MSCs + MLT na fibrose hepática induzida por CCl4. Dos resultados, conclui-se que a terapia combinada de MSCs e MLT mostram um forte efeito terapêutico na fibrose hepática induzida por CCl4, em comparação com MSCs e MLT individualmente.


Subject(s)
Rats , Stem Cells , Fibrosis , Liver , Liver Diseases , Melatonin
9.
Int. j. morphol ; 41(5): 1452-1460, oct. 2023. ilus
Article in Spanish | LILACS | ID: biblio-1521031

ABSTRACT

Lograr determinar el volumen total de un hígado (VHT), o volumetría hepática, pasa a ser de relevancia en diversas situaciones, tales como, vigilancia del progreso de una enfermedad de carácter crónico, planificación de resecciones y trasplantes hepáticos; y observación del clearance hepático de algunos fármacos hepatotropos. La VHT se puede realizar utilizando métodos de segmentación en el curso de una tomografía computarizada (TC), ya sean estos manual, automáticos, y semiautomáticos; mediante resonancia nuclear (RN), utilizando softwares de distintas generaciones (1ª a 4ª). La medición de VHT está indicada en pacientes sometidos a resecciones hepáticas mayores, en el contexto del tratamiento de neoplasias (carcinoma hepatocelular, colangiocarcinoma, metástasis hepáticas o tumores benignos de gran tamaño), abscesos (piogénicos, amebianos), y después de un traumatismo hepático complejo; así como también en la etapa preoperatoria de un trasplante hepático. El objetivo de este manuscrito fue generar un documento de estudio sobre métodos para determinar volumetría hepática.


SUMMARY: Being able to determine the total hepatic volume (THV), or THV, becomes relevant in various situations, such as monitoring the progress of a chronic disease, planning resections and liver transplants; and observation of the hepatic clearance of some hepatotropic drugs. THV can be performed using segmentation methods in the course of a computed tomography (CT), whether manual, automatic, or semi-automated; by nuclear resonance (NR), using software from different generations (1st to 4st). THV measurement is indicated in patients undergoing major liver resections, in the context of treatment of neoplasms (hepatocellular carcinoma, cholangiocarcinoma, liver metastases or large benign tumors), abscesses (pyogenic, amoebic), and after liver trauma complex, as well as in the preoperative stage of a liver transplant. The aim of this manuscript was to generate a study document regarding methods for determine hepatic volumetry.


Subject(s)
Humans , Liver Diseases/diagnostic imaging , Magnetic Resonance Imaging , Tomography, X-Ray Computed , Ultrasonography , Liver/diagnostic imaging , Liver Neoplasms/diagnostic imaging
10.
Medisan ; 27(5)oct. 2023. ilus
Article in Spanish | LILACS, CUMED | ID: biblio-1529009

ABSTRACT

Se presenta el caso clínico de una gestante de 20 años de edad, quien acudió al Cuerpo de Guardia del bloque materno del Hospital General Docente Dr. Juan Bruno Zayas Alfonso de Santiago de Cuba por presentar decaimiento, náuseas y malestar general. Durante la exploración física se encontró piel sudorosa y fría, taquicardia e ictericia. Se realizaron diversos exámenes complementarios y se constató alteración hepática, así como cifras bajas de glucemia. Se diagnosticó hígado graso agudo del embarazo. Luego de varios días de hospitalizada con una evolución desfavorable, hasta llegar al estado crítico, la paciente falleció por síndrome de disfunción multiorgánica.


The case report of a 20 years pregnant woman is presented, who went to the maternal block emergency room of Dr. Juan Bruno Zayas Alfonso Teaching General Hospital in Santiago de Cuba due to run-down, nausea and diffuse discomfort. During the physical exploration sweaty and cold skin, tachycardia and jaundice were found. Diverse complementary exams were carried out and a hepatic disorder was verified, as well as low figures of glycemia. Acute fatty liver of pregnancy was diagnosed. After several days hospitalized with an unfavorable clinical course until getting to the critical state, the patient died due to multiple organ dysfunction syndrome.


Subject(s)
Pregnancy, High-Risk , Fatty Liver , Liver Diseases , Pregnancy , Fetal Death , Maternal Death , Multiple Organ Failure
11.
Rev. méd. Chile ; 151(9): 1255-1259, sept. 2023. ilus
Article in Spanish | LILACS | ID: biblio-1565710

ABSTRACT

Presentamos el caso de un paciente de 49 años, de sexo masculino, que consulta en el servicio de urgencias por un cuadro de dos meses de evolución, caracterizado por compromiso del estado general, baja de peso, dolor abdominal, sensación febril y elevación de los parámetros inflamatorios. Al estudio imagenológico se observa una voluminosa lesión hepática, asociada a dilatación de la vía biliar y adenopatías en hilio hepático, espacio porto-cavo y retroperitoneales (inter-cavo-aórticos), que plantea dentro de los diagnósticos diferencias un colangiocarcinoma intrahepático. Basados en esta sospecha se realiza una segmentectomía y linfadenectomía regional. El estudio histopatológico e inmunohistoquímico de la pieza quirúrgica, evidencia un proceso inflamatorio linfoplasmocitario, con la presencia de células plasmáticas IgG4 positivas, compatible con una enfermedad asociada a IgG4. Posterior a la resección se decide manejo expectante, evolucionando el paciente de forma favorable, asintomático y sin signos de recurrencia. Presentamos un caso y una breve revisión de la literatura de un pseudotumor inflamatorio hepático, entidad poco frecuente y de comportamiento benigno.


We report the case of a 49-year-old man who attended the emergency department for a two-month history of compromised general condition, weight loss, abdominal pain, fever, and elevated inflammatory parameters. An imaging study demonstrates a bulky liver tumor associated with dilation of the bile duct and retroperitoneal adenopathies (hepatic hilum, intermediate, and right lumbar groups). These findings raise intrahepatic cholangiocarcinoma within the differential diagnoses, reason why segmental hepatectomy and regional lymphadenectomy were performed. Histopathology and immunochemistry revealed a lymphoplasmacytic inflammatory process with IgG4-positive plasma cells compatible with IgG4-associated disease. After the resection, expectant management was decided, with the patient evolving favorably, asymptomatic, and without signs of recurrence. We present a case and a brief literature review of an hepatic inflammatory pseudotumor, a rare entity with a benign behavior.


Subject(s)
Humans , Male , Middle Aged , Bile Duct Neoplasms/diagnosis , Bile Duct Neoplasms/pathology , Bile Duct Neoplasms/diagnostic imaging , Cholangiocarcinoma/diagnosis , Cholangiocarcinoma/psychology , Cholangiocarcinoma/diagnostic imaging , Granuloma, Plasma Cell/diagnosis , Granuloma, Plasma Cell/pathology , Granuloma, Plasma Cell/diagnostic imaging , Bile Ducts, Intrahepatic/pathology , Tomography, X-Ray Computed , Diagnosis, Differential , Hepatectomy , Liver Diseases/diagnosis , Liver Diseases/pathology , Liver Neoplasms/diagnosis , Liver Neoplasms/pathology , Liver Neoplasms/diagnostic imaging
12.
Arch. argent. pediatr ; 121(4): e202202905, ago. 2023. ilus
Article in English, Spanish | LILACS, BINACIS | ID: biblio-1442708

ABSTRACT

La fibrosis quística, la segunda enfermedad genética más frecuente, es el resultado de una proteína de canal mutada, la CFTR, que secreta iones de cloro que fluidifican las secreciones. La esperanza de vida en los pacientes ha aumentado en años recientes gracias a mejoras en el tratamiento. No obstante, las complicaciones hepáticas son la tercera causa de muerte y la comprensión de su fisiopatología es aún deficiente. Se considera que la obstrucción biliar secundaria a la presencia de secreciones espesas conduce a la cirrosis. Sin embargo, el ácido ursodesoxicólico no ha modificado la historia natural. Además, la presencia de hipertensión portal en ausencia de cirrosis no puede ser explicada. Se ha propuesto el rol de la CFTR como modulador de tolerancia inmune, que explica la presencia de una inflamación portal persistente que culmina en fibrosis. El eje intestino-hígado tendría un rol importante en la presentación y la progresión de esta enfermedad


Cystic fibrosis is the second most common genetic disease in infancy. It is the result of a mutated channel protein, the CFTR, which secretes chloride ions, fluidifying secretions. Recent improvements in the treatment have increased life expectancy in these patients. Nevertheless, liver involvement remains the third cause of death. Unfortunately, our understating of the physiopathology is still deficient. Biliary obstruction secondary to the presence of thick secretions is considered to lead to cirrhosis. However, treatment with ursodeoxycolic acid has not changed the natural history. Furthermore, the presence of portal hypertension in the absence of cirrhosis cannot be explained. Recently, the role of CFTR as modulator of immune tolerance has been proposed, which could explain the presence of a persistent portal inflammation leading to fibrosis, and the gut-liver axis would also have a role in disease presentation and progression.


Subject(s)
Humans , Cystic Fibrosis , Liver Diseases/etiology , Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Liver Cirrhosis/therapy , Mutation
13.
Rev. méd. Chile ; 151(4): 461-468, abr. 2023. ilus, tab
Article in Spanish | LILACS | ID: biblio-1560202

ABSTRACT

INTRODUCTION: For the diagnosis of liver diseases, clinical criteria, biochemical, immunological and histological parameters are included. The autoimmune panel is an immunoblot that contemplates the detection of antibodies against 9 different hepatic antigens, which could guide the diagnosis of these pathologies. OBJECTIVE: To describe the usefulness of the autoimmune panel in the diagnosis of liver diseases. Methods: Observational, descriptive study. All autoimmune panels performed between January 2020 and August 2021 (n = 279) were reviewed, and the ones with positive result selected (n = 101). Clinical records were reviewed, including: clinical, biochemical, immunological and histological characteristics. Diagnosis was determined by clinical suspicion (clinical, biochemical and immunological parameters), only through autoimmune panel, and according to liver biopsy in available cases. RESULTS: 45 patients with complete clinical history were included in the analysis; 82% women, median age 58 years (16-79). Clinical suspicions included autoimmune hepatitis (AIH) in 12 patients (27%), primary biliary cholangitis (PBC) in 10 patients (22%), overlap syndrome (AIH/PBC) in 17 (38%), and others in 6 (13%). The diagnosis of PBC was confirmed by autoimmune panel in 9/10 and 11/17 patients with clinical suspicion of PBC and HAI/PBC, respectively. Of the 27 patients with initial clinical suspicion of PBC, 14 had negative AMA and AMA-M2 (6 had Sp100 and 5 gp210 as the only markers and 3 had positive Sp100 and PML). In 10/14 patients, the diagnosis was confirmed by panel and/or compatible liver biopsy. CONCLUSION: The autoimmune panel turns out to be a useful diagnostic tool for liver diseases, especially PBC in isolation or in overlap syndrome.


Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Aged , Young Adult , Autoantibodies/blood , Immunoblotting/methods , Hepatitis, Autoimmune/diagnosis , Hepatitis, Autoimmune/immunology , Hepatitis, Autoimmune/blood , Liver Diseases/diagnosis , Liver Diseases/immunology , Autoimmune Diseases/diagnosis , Autoimmune Diseases/immunology , Autoimmune Diseases/blood , Liver Cirrhosis, Biliary/diagnosis , Liver Cirrhosis, Biliary/immunology , Liver Cirrhosis, Biliary/blood
14.
Zhonghua ganzangbing zazhi ; Zhonghua ganzangbing zazhi;(12): 337-338, 2023.
Article in Chinese | WPRIM | ID: wpr-986138

ABSTRACT

As a liver disease with the most complex clinical phenotype, drug-induced liver injury (DILI) poses great challenges in diagnosis and management in clinical practice. Although guidelines based on the latest research advances can provide clinicians with guidance on the identification, diagnosis, and management of DILI, the overall level of evidence in this field is relatively low and high-level evidence is limited. Therefore, we should interpret guidelines with caution and look forward to more clinical and translational research to address the huge unmet clinical needs in DILI.


Subject(s)
Humans , Translational Research, Biomedical , Chemical and Drug Induced Liver Injury/therapy , Liver Diseases , Liver Function Tests
15.
Zhonghua ganzangbing zazhi ; Zhonghua ganzangbing zazhi;(12): 445-448, 2023.
Article in Chinese | WPRIM | ID: wpr-986150

ABSTRACT

Sarcopenia has attracted increasing attention with the study of nutrition in patients with liver disease. Sarcopenia is an independent risk factor for a poor prognosis of liver disease and is becoming increasingly common in patients with liver disease. Studies have shown that patients with liver disease and sarcopenic obesity have a worse prognosis than patients with liver disease and simple sarcopenia or obesity. In clinical practice, it is easy to recognize patients with malnutrition and decreased muscle mass, but we often ignore those patients with normal body weight or even obesity who will likewise experience muscle mass loss. Simply relying on the monitoring of body mass and body mass index to assess the nutritional and muscle status of patients with liver disease is not accurate. At present, our understanding of the relationship between chronic liver disease and sarcopenic obesity is still poorly understood. In this paper, the research progress on chronic liver disease, sarcopenia, and sarcopenic obesity in recent years is reviewed so as to provide a theoretical basis for improving the clinical prognosis of patients with liver disease.


Subject(s)
Humans , Sarcopenia/complications , Body Composition/physiology , Obesity/complications , Risk Factors , Liver Diseases/complications , Muscle, Skeletal
16.
Zhonghua ganzangbing zazhi ; Zhonghua ganzangbing zazhi;(12): 471-476, 2023.
Article in Chinese | WPRIM | ID: wpr-986155

ABSTRACT

Hepatitis type E virus (HEV) is one of the main causes of acute hepatitis globally and has thus gained attention as a public health issue. The diverse clinical manifestations of hepatitis type E are typically acute and self-limiting with mild symptoms, but populations with underlying liver disease or immunocompromised patients can have severe and chronic symptoms. Severity and chronicity can arise and manifest as fulminant hepatitis, chronic hepatitis, or even hepatic failure. HEV infection-induced hepatic failure (acute-on-chronic liver failure), based on the different backgrounds of chronic liver disease, is a clinical phenotype of severe HEV infection that requires attention. In addition, HEV infection can exhibit extrahepatic clinical manifestations of multi-system and organ involvement like neurological diseases (Guillain-Barré syndrome), renal diseases (membranous/membranous proliferative glomerulonephritis, cryoglobulinemia), and blood diseases (thrombocytopenia). At home or abroad, there are no antiviral drugs approved, particularly for HE treatment. Since most acute HE can resolve spontaneously, no special treatment is required clinically. However, in patients with severe or chronic HE, ribavirin (RBV) monotherapy and/or pegylated interferon-combination therapy have achieved certain antiviral effects. Combined small-molecule drugs and RBV have been attempted to treat HEV, but high-level evidence-based treatment is still lacking. Thus, new, highly effective anti-HEV drugs are clinical priorities to address these concerns. Severe and chronic HEV infections' clinical phenotype, early detection, mechanism, intervention, and outcome need additional study.


Subject(s)
Humans , Antiviral Agents/therapeutic use , Ribavirin/therapeutic use , Hepatitis, Chronic/drug therapy , Hepatitis E virus , Liver Diseases/drug therapy , Liver Failure/drug therapy
17.
Zhonghua ganzangbing zazhi ; Zhonghua ganzangbing zazhi;(12): 776-780, 2023.
Article in Chinese | WPRIM | ID: wpr-986211

ABSTRACT

Type II innate lymphoid cell (ILC2) is a newly identified innate immunological cell that belongs to the lymphocyte lineage in cell morphology, resides in the body's mucosal tissues, and has the dual functions of innate and adaptive immunity to promote tissue remodeling and repair after injury. Additionally, it is involved in the occurrence and development of a variety of liver diseases and plays an important role in maintaining the immunological homeostasis of the liver region. This article reviews the differentiation, development, and biological functions of ILC2, with particular attention to the research progress in liver diseases.


Subject(s)
Humans , Immunity, Innate , Lymphocytes , Cell Differentiation , Liver Diseases
18.
Article in Chinese | WPRIM | ID: wpr-986997

ABSTRACT

OBJECTIVE@#To explore the molecular pathological mechanism of liver metabolic disorder in severe spinal muscular atrophy (SMA).@*METHODS@#The transgenic mice with type Ⅰ SMA (Smn-/- SMN20tg/2tg) and littermate control mice (Smn+/- SMN20tg/2tg) were observed for milk suckling behavior and body weight changes after birth. The mice with type Ⅰ SMA mice were given an intraperitoneal injection of 20% glucose solution or saline (15 μL/12 h), and their survival time was recorded. GO enrichment analysis was performed using the RNA-Seq data of the liver of type Ⅰ SMA and littermate control mice, and the results were verified using quantitative real-time PCR. Bisulfite sequencing was performed to examine CpG island methylation level in Fasn gene promoter region in the liver of the neonatal mice.@*RESULTS@#The neonatal mice with type Ⅰ SMA showed normal milk suckling behavior but had lower body weight than the littermate control mice on the second day after birth. Intraperitoneal injection of glucose solution every 12 h significantly improved the median survival time of type Ⅰ SMA mice from 9±1.3 to 11± 1.5 days (P < 0.05). Analysis of the RNA-Seq data of the liver showed that the expression of the target genes of PPARα related to lipid metabolism and mitochondrial β oxidation were down-regulated in the liver of type Ⅰ SMA mice. Type Ⅰ SMA mice had higher methylation level of the Fasn promoter region in the liver than the littermate control mice (76.44% vs 58.67%). In primary cultures of hepatocytes from type Ⅰ SMA mice, treatment with 5-AzaC significantly up-regulated the expressions of the genes related to lipid metabolism by over 1 fold (P < 0.01).@*CONCLUSION@#Type Ⅰ SMA mice have liver metabolic disorder, and the down-regulation of the target genes of PPARα related to lipid and glucose metabolism due to persistent DNA methylation contributes to the progression of SMA.


Subject(s)
Mice , Animals , PPAR alpha , Liver Diseases , Muscular Atrophy, Spinal/genetics , Mice, Transgenic , Body Weight , Glucose
19.
Zhonghua ganzangbing zazhi ; Zhonghua ganzangbing zazhi;(12): 35-41, 2023.
Article in Chinese | WPRIM | ID: wpr-970949

ABSTRACT

What are the new contents of the guideline since 2010?A.Patients with primary and non-primary sclerosing cholangitis (PSC) are included in these guidelines for the diagnosis and management of cholangiocarcinoma.B.Define "related stricture" as any biliary or hepatic duct stricture accompanied by the signs or symptoms of obstructive cholestasis and/or bacterial cholangitis.C.Patients who have had an inconclusive report from MRI and cholangiopancreatography should be reexamined by high-quality MRI/cholangiopancreatography for diagnostic purposes. Endoscopic retrograde cholangiopancreatography should be avoided for the diagnosis of PSC.D. Patients with PSC and unknown inflammatory bowel disease (IBD) should undergo diagnostic colonoscopic histological sampling, with follow-up examination every five years until IBD is detected.E. PSC patients with IBD should begin colon cancer monitoring at 15 years of age.F. Individual incidence rates should be interpreted with caution when using the new clinical risk tool for PSC for risk stratification.G. All patients with PSC should be considered for clinical trials; however, if ursodeoxycholic acid (13-23 mg/kg/day) is well tolerated and after 12 months of treatment, alkaline phosphatase (γ- Glutamyltransferase in children) and/or symptoms are significantly improved, it can be considered to continue to be used.H. Endoscopic retrograde cholangiopancreatography with cholangiocytology brushing and fluorescence in situ hybridization analysis should be performed on all patients suspected of having hilar or distal cholangiocarcinoma.I.Patients with PSC and recurrent cholangitis are now included in the new unified network organ sharing policy for the end-stage liver disease model standard.J. Liver transplantation is recommended after neoadjuvant therapy for patients with unresectable hilar cholangiocarcinoma with diameter < 3 cm or combined with PSC and no intrahepatic (extrahepatic) metastases.


Subject(s)
Child , Humans , Cholangitis, Sclerosing/diagnosis , Constriction, Pathologic/complications , In Situ Hybridization, Fluorescence , Cholangiocarcinoma/therapy , Liver Diseases/complications , Cholestasis , Inflammatory Bowel Diseases/therapy , Bile Ducts, Intrahepatic/pathology , Bile Duct Neoplasms/therapy
20.
Zhonghua ganzangbing zazhi ; Zhonghua ganzangbing zazhi;(12): 96-100, 2023.
Article in Chinese | WPRIM | ID: wpr-970958

ABSTRACT

Objective: To analyze the characteristics of scientific papers in the field of global liver diseases published by Chinese scholars that were retracted for diverse reasons from the Retraction Watch database, so as to provide a reference to publishing-related papers. Methods: The Retraction Watch database was retrieved for retracted papers in the field of global liver disease published by Chinese scholars from March 1, 2008 to January 28, 2021. The regional distribution, source journals, reasons for retraction, publication and retraction times, and others were analyzed. Results: A total of 101 retracted papers that were distributed across 21 provinces/cities were retrieved. Zhejiang area (n = 17) had the most retracted papers, followed by Shanghai (n = 14), and Beijing (n = 11). The vast majority were research papers (n = 95). The journal PLoS One had the highest number of retracted papers. In terms of time distribution, 2019 (n = 36) had the most retracted papers. 23 papers, accounting for 8.3% of all retractions, were retracted owing to journal or publisher concerns. Liver cancer (34%), liver transplantation (16%), hepatitis (14%), and others were the main areas of retracted papers. Conclusion: Chinese scholars have a large number of retracted articles in the field of global liver diseases. A journal or publisher chooses to retract a manuscript after investigating and discovering more flawed problems, which, however, require further support, revision, and supervision from the editorial and academic circles.


Subject(s)
Humans , Biomedical Research , China , Liver Diseases , Scientific Misconduct
SELECTION OF CITATIONS
SEARCH DETAIL